**Supplementary Data**

**A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides**

Malik Zohaib Ali 1,2,6, Taru S. Dutt 1,2, Amy MacNeill 2, Amanda Walz 1,2, Camron Pearce 1,2.6, Ha Lam1,2, Jamie Philp 1,2, Johnathan Patterson 1,2, Marcela Henao-Tamayo 2, Richard E. Lee 3, Jiuyu Liu 3, Gregory T. Robertson 1,2, Anthony J. Hickey 4, Bernd Meibohm 5, Mercedes Gonzalez-Juarrero 1,2

1Mycobacteria Research Laboratories, Colorado State University, 80523, USA

2Microbiology, Immunology and Pathology, Colorado State University, 80523, USA

3Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, 38105, USA

4Technology Advancement and Commercialization, RTI International, 27709, USA

5Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 38163, USA

6Program in Cell & Molecular Biology, Colorado State University, 80523, USA

**Supplementary File 1**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Antibody** | **Specie** | **Type** | **Company** | **Catalogue #** | **Concentration** | **pH** | **Opal** |
| CD8 | Rabbit | mAb | CST | D4W2Z | 1:400 | 6 | 480 |
| CD4 | Rat | mAb | Thermo Fisher | 4SM95 | 1:200 | 6 | 520 |
| B220 | Rat | mAb | BD Pharm | RA3-6B2 | 1:500 | 6 | 570 |
| FoxP3 | Rabbit | mAb | R&D | MAB8214 | 1:200 | 6 | 620 |
| Ly6G | Rabbit | mAb | CST | 87048 | 1:100 | 6 | 690 |
| F4/80 | Rabbit | mAb | CST | D4C8V | 1:100 | 6 | 780 |